Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

被引:0
作者
Mohammad Tabrizi
Gadi Gazit Bornstein
Hamza Suria
机构
[1] AnaptysBio,Preclinical Development (MT) and Corporate Development (HS)
[2] Inc.,Cancer Biologics
[3] Astrazeneca R&D Boston,undefined
[4] PLC,undefined
来源
The AAPS Journal | 2010年 / 12卷
关键词
biodistribution; monoclonal antibodies; pharmacokinetics and pharmacodynamics; tumor penetration;
D O I
暂无
中图分类号
学科分类号
摘要
The monoclonal antibody market continues to witness an impressive rate of growth and has become the leading source of expansion in the biologic segment within the pharmaceutical industry. Currently marketed monoclonal antibodies target a diverse array of antigens. These antigens are distributed in a variety of tissues such as tumors, lungs, synovial fluid, psoriatic plaques, and lymph nodes. As the concentration of drug at the proximity of the biological receptor determines the magnitude of the observed pharmacological responses, a significant consideration in effective therapeutic application of monoclonal antibodies is a thorough understanding of the processes that regulate antibody biodistribution. Monoclonal antibody distribution is affected by factors such as molecular weight, blood flow, tissue and tumor heterogeneity, structure and porosity, target antigen density, turnover rate, and the target antigen expression profile.
引用
收藏
页码:33 / 43
页数:10
相关论文
共 365 条
[1]  
Mascelli MA(2007)Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development J Clin Pharmacol 47 553-565
[2]  
Zhou H(2009)Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-{alpha} human monoclonal antibody, in patients with psoriatic arthritis J Clin Pharmacol 49 1056-1070
[3]  
Sweet R(2006)Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis Br J Clin Pharmacol 62 435-445
[4]  
Getsy J(2005)Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein J Clin Pharmacol 45 490-497
[5]  
Davis HM(2004)Next-generation protein drugs Nat Biotechnol 22 521-522
[6]  
Graham M(1987)Transport of molecules in the tumor interstitium: a review Cancer Res 47 3039-3051
[7]  
Xu Z(1987)Transport of molecules across tumor vasculature Cancer Metastasis Rev 6 559-593
[8]  
Vu T(1986)Extravascular transport in normal and tumor tissues Crit Rev Oncol Hematol 5 115-170
[9]  
Lee H(2009)Application of translational biomarkers in development of antibody-based therapeutics Drug Discov 5 2-6
[10]  
Hu C(2009)Translational strategies for development of monoclonal antibodies from discovery to the clinic Drug Discov Today 14 298-305